ScholarIQanswers from OpenAlex & ORCID
Alexa B. Kimball
ResearcherPublications, citations & collaboration network
Alexa B. Kimball is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Alexa B. Kimball have?
ScholarIQindexed works
Alexa B. Kimball has 550 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Alexa B. Kimball have?
ScholarIQcitation count
Alexa B. Kimball has 28,794 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Alexa B. Kimball?
ScholarIQh-index
Alexa B. Kimball has an h-index of 82 in OpenAlex.
What is the i10-index of Alexa B. Kimball?
ScholarIQi10-index
Alexa B. Kimball has an i10-index of 298 in OpenAlex.
What is the ORCID of Alexa B. Kimball?
ScholarIQorcid
The ORCID for Alexa B. Kimball is on the source record.
What is the OpenAlex record for Alexa B. Kimball?
ScholarIQopenalex
The OpenAlex for Alexa B. Kimball is on the source record.
What are the most-cited papers on Alexa B. Kimball?
ScholarIQmost cited works
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi, Alexa B. Kimball, Kim Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Alexa B. Kimball, Martin M. Okun, David Williams, Alice B. Gottlieb, Kim Papp, Christos C. Zouboulis, April W. Armstrong, Francisco A. Kerdel, Michael H. Gold, Seth Forman, Neil J. Korman, Evangelos J. Giamarellos‐Bourboulis, Jeffrey Crowley, Charles Lynde, Z. Reguiaï, Errol-Prospero Prens, Eihab Alwawi, Nael M. Mostafa, Brett Pinsky, Murali Sundaram, Yihua Gu, Dawn M. Carlson, Gregor B. E. Jemec